Dr. Matthias Bureik received his Ph.D. from the Department of Medical Biochemistry of Saarland University Medical Hospital in Homburg, Germany, with a thesis on the human tumour suppressor protein p53. He then worked as a postdoc and as a senior scientist on cytochrome P450 systems in the lab of Rita Bernhardt in Saarbrücken, where he habilitated in 2007. From 2008 to 2012 he was CEO of a biotech start-up company. Since July 2014 he is Professor of Biochemistry at the School of Pharmaceutical Science and Technology of Tianjin University in China. His research topics encompass the study of human drug metabolizing enzymes, especially cytochrome P450 enzymes (CYPs or P450s), which are the most important enzymes involved in the phase I metabolism of drugs and poisons in humans, and UDP glycosyltransferases (UGTs), which catalyze the majority of phase II reactions. His group also works on the development of a new treatment of breast cancer by making use of CYP4Z1-activated prodrugs. Matthias has strong expertise in molecular biology, biotechnology and drug metabolism. Work completed by him and his team has led to the generation of two biotechnology companies and numerous authored and co-authored publications. He has produced valuable intellectual property, where he is a co-inventor on eight patent applications in various fields of research; he is also an expert grant writer with transformative ideas. While not in the institute, he spends his free time reading, playing chess, and spending time with friends and family.
Drug metabolism; Drug discovery and development; Molecular biology; Biochemistry and Biotechnology.